热门资讯> 正文

BioNTech展望催化剂丰富的2026年，推进多产品肿瘤学战略

2026-01-12 20:01

BioNTech(BNTX) 0

BioNTech SE (BNTX) said Monday it will continue executing its strategy in 2026 to evolve into a multi-product oncology company, with the year expected to be catalyst-rich as late-stage programs advance across immunomodulators, antibody-drug conjugates, and mRNA-based cancer therapies.
The company also reported financial strength with €17.2 billion in cash and cash equivalents plus security investments, a COVID-19 vaccine revenue streams, disciplined R&D spend, and strategic partnerships that will continue to enable sustainable innovation.

More on BioNTech

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript
BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold
FDA Commissioner Makary says 'black box' warning not coming to COVID vaccines
FDA plans to put “black box” warning on Covid vaccines: report

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。